

Express Mail Label No.: EV 330 994 754 US  
Date: October 16, 2003

Attorney Docket No. VPI/00-127 CON DIV US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: James Janetka, et al.  
DIVISIONAL APPLICATION OF: 09/971,497 EXAMINER: Sonya Wright  
FILING DATE: Herewith ART UNIT: 1626  
FOR: PYRAZOLE COMPOUNDS USEFUL AS INHIBITORS OF ERK

October 16, 2003  
Cambridge, Massachusetts 02139-4242

MS PATENT APPLICATION  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Information Disclosure Statement is being been filed:

- ☐ within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- ☒ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. 37 C.F.R. §1.97.


A copy of the references are enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

**APPLICANTS:**       **Janetka, et al.**  
**U.S.S.N.:**         **Not Yet Assigned**

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0725, Reference No. VPI/00-127 CON DIV US.

Respectfully submitted,



Andrea L. C. Robidoux, Reg. No. 47,902  
Agent for Applicants  
c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139-4242  
Tel: (617) 444-6731  
Fax: (617) 444-6483

Express Mail Label No.: EV 330 994 754 US  
Date: October 16, 2003

Attorney Docket No. VPI/00-127 CON DIV US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: James Janetka, et al.  
DIVISIONAL APPLICATION OF: 09/971,497 EXAMINER: Sonya Wright  
FILING DATE: Herewith ART UNIT: 1626  
FOR: PYRAZOLE COMPOUNDS USEFUL AS INHIBITORS OF ERK

October 16, 2003  
Cambridge, Massachusetts 02139-4242

MS PATENT APPLICATION  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Information Disclosure Statement is being been filed:

- ☐ within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- ☒ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. 37 C.F.R. §1.97.


A copy of the references are enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

APPLICANTS:     Janetka, et al.  
U.S.S.N.:       Not Yet Assigned

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0725, Reference No. VPI/00-127 CON DIV US.

Respectfully submitted,



Andrea L. C. Robidoux, Reg. No. 47,902  
Agent for Applicants  
c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139-4242  
Tel: (617) 444-6731  
Fax: (617) 444-6483

Modified Form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	Not Yet Assigned
	<b>Filing Date</b>	Herewith
	<b>First Named Inventor</b>	Michael R. Hale
	<b>Group Art Unit</b>	1626
	<b>Examiner Name</b>	Sonya Wright
	<b>Attorney Docket Number</b>	VPI-00-127 CON DIV US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1*	5,922,741	07/13/99	Davis, et al.			

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	Translation No	
	B1*	2 707 295 A	Rhone Poulenc Agrochimie	13-Jan-1995		X	
	B2*	WO 98/52941	PCT	26-Nov-1998			

OTHER NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
	C1*	Shurov, S.N., et al., "Five -Membered-Ring 2, 3-Dioxoheterocycles. XXXV. Reaction of 5-Aryl-2, 3-Dihydro-2, 3-Furandiones with Ketene Acetals. Synthesis, Structure and Heterocyclization Reactions of 5-Aryl-Hydroxy-3-Oxo-2, 3-Dihydrofuran-2-YL Acetic Acid Alkyl Esters", Zurnal Organiceskoj Khimii, Maik, Nauka, Moscow, RU, pp. 2275-2289 (1993).					
	C2*	Andreichikov, Y.S., et al., "Synthesis of 3(2,3-dihydro-3-oxo-5-pyrazolyl)-4-methyl-5-arylpyrazoles", Zurnal Organiceskoj Khimii, Maik Nauka, Moscow, RU, 21(10):2241-2242 (1985).					
	C3*	Kozminykh, V.O. , Khim. Geterotsikl. Soedin., 8: 1031-1038 (1992).					
	C4*	Shevelev, S.A., et al., "Nitro Derivatives of Bi-, Ter-, and Quarterpyrazoles", Russian Chem. Bulletin, Plenum, Publishing Co., NY, NY, US, 42(11):1857-1861 (1993).					
	C5*	Ajello, E., "New Syntheses of Condensed Heterocycles from Isoxazole Derivatives.II. Pyrazolo4, 3-B Pyridine", J. of Heterocyclic Chemistry, Heterocorporation. Provo, US, 8:1035-1037 (1971).					
	C6*	Polanc, S., "A Novel Method for the Annelation of the 1, 2, 4-triazole ring of the N2-C3 bond to azines", J. Org. Chem., 39(15):2143-2147 (1974).					
	C7*	Monge, M.A., "An X-Ray and <sup>13</sup> C CP/MAS NMR Study of C, C-linked bipyrazoles and bispyrazolymethanes", Spectrochimica ACTA, 50a(4):727-734 (1994).					

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. 09/971,497, filed October 5, 2001, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.